MedTrace Logo

Economic Analyses of the REDUCE Trial

NCT01337258 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2017-05-30

No results posted yet for this study

Summary

The objective of this project is to conduct a retrospective economic analysis of the use of dutasteride for the prevention of prostate cancer based on data from the REDUCE clinical trial. REDUCE is a 4-year, phase 3, randomized, double-blind, parallel assignment clinical trial of the use of dutasteride compared with no chemopreventive treatment.

The REDUCE trial was a four-year, international, multicenter, randomized, double-blind, placebo-controlled, parallel group study. There were 790 investigators in 42 countries.

Conditions

  • Neoplasms, Prostate
  • Benign Prostatic Hyperplasia
  • Cancer

Interventions

DRUG

Dutasteride

dutasteride 0.5mg daily.

DRUG

Placebo

Men taking placebo daily

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-07-31
Completion
2010-07-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01337258 on ClinicalTrials.gov